References in periodicals archive ?
(Nasdaq: MDGL) is a clinical-stage biopharmaceutical company pursuing novel therapeutics that target a specific thyroid hormone receptor pathway in the liver, which is a key regulatory mechanism common to a spectrum of cardio-metabolic and fatty liver diseases with high unmet medical need.
Score questionnaire for FN, PN, PTGL for RAPID 3; add PTJT for RAPID 4; and MDGL for RAPID 5 described above, using scoring templates in the "For Office Use Only" boxes at the right side.
He believes Viking's data could be superior to Madrigal Pharmaceuticals' (MDGL).
Richter this morning also downgraded Madrigal Pharmaceuticals (MDGL) to Neutral from Buy.
The analyst believes that by Q4 of 2019, only three meaningful non-alcoholic steatohepatitis pivotal programs will be in development: Allergan's (AGN) cenicriviroc, Madrigal Pharmaceuticals' (MDGL) MGL-3196, and Galmed's Aramchol.
After Bloomberg reported that Madrigal Pharmaceuticals (MDGL) is exploring a sale after receiving takeover interest, H.C.
Shares of Madrigal Pharmaceuticals (MDGL) jumped after Bloomberg reported, citing people familiar with the matter, that the company is working with Centerview Partners on a potential sale after receiving takeover interest.
That valuation may be viewed as "conservative" given the rise in valuations of others in the NASH space, including Madrigal (MDGL), which McCarthy said completed a Phase 2 study that was "smaller and shorter" than Galmed.
Roth Capital analyst Yasmeen Rahimi noted that Madrigal Pharmaceuticals' (MDGL) "impressive" NASH resolution results published yesterday resulted in the stock's value being pushed up to make it the highest among "purely NASH" companies.
Roth Capital analyst Scott Henry maintained a Buy rating on Viking Therapeutics while raising his price target to $13 from $7.50 saying the data yesterday from Madrigal Pharmaceuticals (MDGL) appears to validate the class of Thyroid Hormone Receptor Beta agonist compounds, noting that Viking's VK2809 is a similar agonist.
Shares of Madrigal Pharmaceuticals (MDGL) are soaring after the company announced positive top-line, 36-week results from a Phase 2 clinical trial in patients with biopsy-proven non-alcoholic steatohepatitis.
Madrigal Pharmaceuticals (MDGL), up 56% after reporting top-line, 36-week results from a Phase 2 clinical trial in patients with biopsy-proven non-alcoholic steatohepatitis, or NASH.
Acronyms browser ?
Full browser ?